Clinical Scorecard: A multicenter, open-label observational trial assessing the safety and effectiveness of LivaloZet® tablets in individuals with dyslipidemia and metabolic syndrome: Protocol for the PIVOT study

At a Glance

Key Highlights

• LivaloZet® Tablet combines pitavastatin and ezetimibe for effective LDL-C reduction.
• The study aims to enroll up to 10,000 patients.
• Primary endpoint is the percent change in LDL-C from baseline at Week 24.
• Safety assessments include monitoring for hepatotoxicity and myopathy.
• The study will provide real-world evidence on the effectiveness and safety of LivaloZet®.

Guideline-Based Recommendations

Diagnosis

• Dyslipidemia defined by elevated LDL-C, triglycerides, or reduced HDL-C.

Management

• Combination therapy with statins and ezetimibe is recommended for LDL-C reduction.

Monitoring & Follow-up

• Systematic monitoring of AST, ALT, and creatine kinase for statin-related side effects.

Risks

• Potential for dose-dependent hepatotoxicity and rhabdomyolysis with statins.

Patient & Prescribing Data

Korean adults with dyslipidemia and metabolic syndrome.

LivaloZet® is indicated for patients requiring potent LDL-C reduction or those unable to tolerate high-dose statins.

Clinical Best Practices

• Utilize fixed-dose combinations for improved adherence and efficacy.
• Assess glucose metabolism in patients with metabolic syndrome on lipid-lowering therapy.

Related Resources & Content

• ClinicalTrials.gov